IP Library Granted Patent US 7,273,695
Granted Patent B1
US 7,273,695 · App. 08/089,407 · Granted Sep 25, 2007

HIV immunoassays using synthetic envelope polypeptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,273,695
App. No.
08/089,407
Granted
Sep 25, 2007
Kind
B1
Abstract

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.

Claims (14)

1. In an immunoassay to detect the presence of antibodies to a human immunodeficiency virus (HIV) in a human sample comprising contacting said sample with an envelope (env) antigen comprising an amino acid sequence from the env domain of said HIV and determining whether antibodies are bound to said env antigen, the improvement comprising employing as said env antigen a synthetic polypeptide comprising an antigenic amino acid sequence from the env domain of HIV as shown in FIG. 4 .

2. A method of detecting antibodies to a human immunodeficiency virus (HIV) in a human sample, comprising:

a) providing a solid support having bound thereto a synthetic polypeptide comprising an envelope env antigen comprising an antigenic amino acid sequence of the env domain of HIV as shown in FIG. 4 , wherein said env antigen is a synthetic polypeptide;

b) contacting said solid support with said human sample to provide a sample-contacted support;

c) washing said sample-contacted support to provide a washed support; and

d) determining whether human antibodies are bound to said washed support.

3. The method of claim 1 wherein said human sample comprises serum.

4. The method of claim 2 wherein said human sample comprises serum.

5. The method of claim 1 wherein step (d) comprises contacting said washed support with labeled antibodies to human Ig and the specific binding of said labeled antibodies to said washed support is measured.

6. The method of claim 2 wherein step (d) comprises contacting said washed support with labeled antibodies to human Ig and the specific binding of said labeled antibodies to said washed support is measured.

7. An article of manufacture adapted for use in an immunoassay for antibodies to a human immunodeficiency virus (HIV) comprising a solid support having bound thereto to synthetic polypeptide comprising at least a portion of an envelope (env) antigen comprising an antigenic amino acid sequence of the env domain of said HIV, wherein said env antigen is a synthetic polypeptide comprising an antigenic amino acid sequence from the env domain of HIV as shown in FIG. 4 .

8. The immunoassay of claim 1 wherein said env antigen contains at least 15 amino acid residues.

9. The method of claim 2 wherein said env antigen contains at least 15 amino acid residues.

10. The article of manufacture of claim 7 wherein said env antigen contains at least 15 amino acid residues.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE AND ASSIGNOR. PREVIOUSLY RECORDED ON REEL 033886 FRAME 0313. ASSIGNOR(S) HEREBY CONFIRMS THE CONFIRMATORY ASSIGNMENT. Recorded Oct 20, 2014
From: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.; GRIFOLS WORLDWIDE OPERATIONS LIMITED
Reel/Frame 034116/0974 →
CONFIRMATORY ASSIGNMENT Recorded Oct 2, 2014
From: NOVARTIS VACCINES AND DIAGNOSTICS, INC.; NOVARTIS AG
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.; NOVARTIS AG; GRIFOLS WORLDWIDE OPERATIONS LIMITED
Reel/Frame 033886/0313 →
CHANGE OF NAME Recorded Aug 10, 2007
From: CHIRON CORPORATION
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 019684/0926 →
MERGER Recorded Nov 15, 2006
From: NOVARTIS BIOTECH PATERNERSHIP, INC.
To: CHIRON CORPORATION
Reel/Frame 018523/0226 →